To confirm our finding of the increased expression of IGF1 by CSF cells of ITMTX treated patients, we quantified IGF1 protein in CSF samples derived from 19 untreated and 20-ITMTX-treated progressive MS patients. This evidence concerns the gene IGF1 and myeloid sarcoma.